

1 **SUPPLEMENTARY APPENDIX.**

2 Antigen-based multiplex strategies to discriminate SARS-CoV-2 natural and vaccine induced  
3 immunity from seasonal human coronavirus humoral responses

4 Eric D. Laing<sup>1\*</sup>, Spencer L. Sterling<sup>1,2</sup>, Stephanie A. Richard<sup>2,3</sup>, Nusrat J. Epsi<sup>2,3</sup>, Si'Ana  
5 Coggins<sup>1,2</sup>, Emily C. Samuels<sup>1,2</sup>, Shreshta Phogat<sup>1,2</sup>, Lianying Yan<sup>1,2</sup>, Nicole Moreno<sup>2,3</sup>, Christian  
6 L. Coles<sup>2,3</sup>, Matthew Drew<sup>4</sup>, Jennifer Mehalko<sup>4</sup>, Caroline E. English<sup>2,3</sup>, Scott Merritt<sup>2,3,5</sup>, Katrin  
7 Mende<sup>2,3,5</sup>, Vincent J. Munster<sup>6</sup>, Emmie de Wit<sup>6</sup>, Kevin K. Chung<sup>7</sup>, Eugene V. Millar<sup>2,3</sup>, David R.  
8 Tribble<sup>3</sup>, Mark P. Simons<sup>1,3</sup>, Simon D. Pollett<sup>2,3</sup>, Brian K. Agan<sup>2,3</sup>, Dominic Esposito<sup>4</sup>, Charlotte  
9 Lanteri<sup>2</sup>, G. Travis Clifton<sup>5</sup>, Edward Mitre<sup>1</sup>, Timothy H. Burgess<sup>2</sup>, and Christopher C. Broder<sup>1\*</sup>

10

11

12

13

14

15 **Table S1. β-CoV MMIA performance**

		SARS-CoV-2 PCR Status/Archival Sera		
SARS-CoV-2 spike IgM Antibody Test		Positive	Negative	Total
	Positive	110	0	110
	Negative	40	84	124
	Total	150	84	234
	Sensitivity	73.33%		
	Specificity	100.00%		

16

17 **Table S2. IgG and IgM seropositivity within 28 days post-symptom onset (dspo)**

dspo	IgG+	IgG+/IgM+
7 – 14	80.0% (12/15)	73.3% (11/15)
15 – 28	100% (31/31)	93.5% (29/31)

18

19

20

21


22

23

24

25

26



39 **Figure S1. 99.7% probability distribution threshold cutoffs for SARS-CoV-2 antigen**

40 **reactive IgG.** Convalescent serum samples ( $n=43$ ) from SARS-CoV-2 naïve ARIC subjects with  
41 HCoV PCR-confirmed infections were tested with MMIA indicated in panels. Antigens shown as  
42 follows: **(A)** SARS-CoV-2 spike (S-2P), **(B)** SARS-CoV-2 spike (S-2P), **(C)** SARS-CoV-2 RBD,  
43 and **(D)** SARS-CoV-2 NP; solid lines indicate the mean+3SD (99.7%) MFI.


44

45


46

47

48



59                   **Figure S2. Receiver operating characteristic (ROC) curve analysis of SARS-CoV-2 PCR-  
60 positive and -negative serum samples from the EPICC study provided a second  
61 measurement of threshold cutoffs for SARS-CoV-2 antigen reactive IgG.** EPICC Sera were  
62 tested with MMIA indicated in panels; antigens shown as follows: **(A)** SARS-CoV-2 spike (S-  
63 2P), **(B)** SARS-CoV-2 spike (S-2P), **(C)** SARS-CoV-2 RBD, and **(D)** SARS-CoV-2 N



77 **Figure S3. SARS-CoV-2 spike reactive IgM detection with the  $\beta$ -CoV MMIA.**

78 **(A)** ROC curve analysis of SARS-CoV-2 spike protein IgM antibody reactivity in a  $\beta$ -CoV MMIA.

79 PCR-confirmed SARS-CoV-2 positive and negative serum samples ( $n= 105$ ) were tested and  
 80 100% specificity was achieved at threshold cutoff of 1446 MFI. **(B)** SARS-CoV-2 naïve ARIC  
 81 HCoV PCR-positive convalescent serum samples ( $n=43$ ) were tested to establish a 99.7%  
 82 probability threshold (840 MFI). **(C)** ARIC ( $n=84$ ), SARS-CoV-2 PCR-positive EPICC ( $n=116$ )  
 83 and JMS ( $n=35$ ) serum samples were tested in technical duplicates.

84

85

86

87

88

89

90

91

92

93

94